Total amount: € 0,00
HOW TO ORDER
A Journal on Obstetrics and Gynecology
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Scopus, Emerging Sources Citation Index
Minerva Ginecologica 2007 June;59(3):205-14
Evaluation of the climacteric symptomatology modifications and clinical-instrumental parameters in women in physiological menopause treated with hormone replacement therapy with nomegestrol acetate and in surgical menopause treated with estrogen replacement therapy. Part I
Savoca S., D’Agosta S., Lombardo G.
Unità per gli Studi sulla Menopausa, Clinica Ostetrica e Ginecologica II, Dipartimento di Ostetricia, Ginecologia e Scienze Radiologiche, Azienda Ospedaliero-Universitaria
“Gaspare Rodolico” , Policlinico di Catania, Catania, Italia
Aim. The purpose of this study was to evaluate the effect of the use of nomegestrol acetate in relation to climacteric symptomatology, at clinical, instrumental and hematochemical levels. Regarding patients in physiological menopause treated with hormone replacement therapy (HRT) compared to patients in surgical menopause treated with hemihydrate estradiol hormone replacement therapy (ERT) administered transdermally.
Methods. Sixty women in menopause for at least 6 months between the ages of 40 and 55 years were enrolled in the study; 30 women were given HRT with nomegestrol acetate and 30 were only given ERT as they had undergone a total hysterectomy with a bilateral adnexectomy. The standards for inclusion were levels of FSH ≥ to 30 UI, levels of 17B-estradiol ≤ to 50 pg/mL, in women who hadn’t had any hormonal treatment for osteoporosis in the last 6 months. The women were tested at the beginning of the therapy, at 6 months and after 12 months.
Results. In the patients treated with nomegestrol acetate the climacteric symptoms were reduced or had disappeared and the quality of life both as to relationship and sexuality had improved after 12 months. In the group of women who had only been treated with ERT there was a significant reduction of the climacteric symptoms and the subjective symptoms had improved within 6 months and the reduction continued at the follow-up at 12 months.
Conclusion. This study confirms the value of hormone replacement therapy in both groups, underlining a more remarkable improvement in the patients treated with nomegestrol acetate than in those treated with estrogens only.